


US App. No. 10/517,328
Response to 12/14/07 Office Action

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-12 (Cancelled)

13. (Withdrawn) A method of specifically inhibiting Rsk activity, said method comprising the step of contacting a Rsk enzyme with a compound represented by the general structure:



wherein R is H or OH, and R₁, R₂ and R₃ are independently selected from the group consisting of hydroxy -OCOR₄, -COR₄ and C₁-C₄ alkoxy; and
R₄ is H or C₁-C₄ alkyl.

14. (Withdrawn) The method of claim 13, wherein R is H or OH and R₁, R₂ and R₃ are independently selected from the group consisting of hydroxy and -OCOCH₃.

15. (Withdrawn) The method of claims 13 or 14 wherein R is H.


16. (Withdrawn) The method of claims 13, 14 or 15, wherein R₃ is -OCOCH₃.

17-20. (Cancelled).

21. (Currently Amended) A method for treating a cancer characterized by excessive Rsk activity, said method comprising the step of administering to a human or other mammal, in

US App. No. 10/517,328
Response to 12/14/07 Office Action

need thereof having a cancer characterized by excessive Rsk activity and selected from the group consisting of breast, prostate, leukemia, lung, colon, brain, melanoma, ovarian, and kidney, a composition comprising a compound represented by the general structure:



wherein R is H or OH, and R₁, R₂ and R₃ are independently selected from the group consisting of hydroxy, -OCOCH₃, -COCH₃, C₁-C₄ alkoxy, -O-glucoside and -O-rhamnoside in an amount effective for specifically inhibiting Rsk activity in the cells of said human or mammal.

22. (Original) The method of claim 21 wherein R is H and R₁, R₂ and R₃ are independently selected from the group consisting of hydroxy and -OCOCH₃.

23. (Original) The method of claim 21 wherein R is H or OH, R₁ and R₂ are independently hydroxy or -OCOCH₃ and R₃ is -OCOCH₃.

24. (Original) The method of claim 23 wherein R is H.

25. (Currently Amended) A method for treating a cancer characterized by excessive Rsk activity, said method comprising the step of administering to a patient, in need thereof having a cancer characterized by excessive Rsk activity and selected from the group consisting of breast, prostate, leukemia, lung, colon, brain, melanoma, ovarian, and kidney, a composition comprising a Rsk specific inhibitor in an amount effective for specifically inhibiting Rsk activity.

US App. No. 10/517,328
Response to 12/14/07 Office Action

26. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises a compound selected from the group consisting of an anti-sense oligonucleotide and an interfering oligonucleotide.

27. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises an interfering oligonucleotide directed against Rsk1, Rsk2, Rsk3 or Rsk4.

28. (Original) The method of claim 25 wherein the Rsk specific inhibitor comprises an extract from the tissues of *Forsteronia refracta* or *Zingiber zerumbet*.

29-31. (Canceled)


32. (Currently Amended) The method of claim 21 25 further comprising the steps of administering said human or other mammal patient an additional anti-tumor therapy.

33-50 (Canceled)


51. (Previously presented) The method of claim 21, wherein said cancer is selected from the group consisting of breast cancer, prostate cancer, and sarcoma.

52. (Previously presented) The method of claim 51, wherein said Rsk inhibitor is selected from the group consisting of SL0101-1, SL0101-2, and SL0101-3, having the following structures:

US App. No. 10/517,328
Response to 12/14/07 Office Action




SL0101-1



SL0101-2

and



SL0101-3

53. (Previously presented) The method of claim 25, wherein said cancer is selected from the group consisting of breast cancer, prostate cancer, and sarcoma.